CONDUIT PHARMACEUTICALS INC. (CDT) - Dilution Analysis

8-K filing: Stock split 1-for-25 | Outstanding: 1,629,402 → 65,176

8-K filing: CDT Equity Inc. entered into an amendment to a directed stock purchase agreement to lower the floor price to $0.60, potentially issuing up to 41,666,667 shares of common stock, and issued a Senior Secured Convertible Promissory Note with a total principal amount of up to $555,556 to an institutional investor, convertible into shares of common stock upon stockholder approval.

8-K filing: CDT Equity Inc. issued 224,800 shares of common stock and 3,685,815 pre-funded warrants to Corvus Capital Limited in connection with the sale of Conduit Pharmaceuticals Limited for a settlement amount of $7,000,000. ($14.0M proceeds)

10-Q filing | 1.6M shares outstanding

8-K filing: Stock split 1-for-8 | Outstanding: 3,062,025 → 382,753

10-Q filing | 3.1M shares outstanding

S-3 filing: This prospectus relates to the offer and resale of up to an aggregate of 255,285 shares of common stock of Conduit Pharmaceuticals Inc. held by the selling stockholders.

8-K filing: Conduit Pharmaceuticals Inc. issued 154,799 shares of its common stock to Manoira Corporation in exchange for approximately $500,000 of consideration under a joint development agreement. ($0.5M proceeds)

8-K filing: Stock split 1-for-15 | Outstanding: 11,961,460 → 797,430

10-Q filing | 12.0M shares outstanding

S-3 filing: This prospectus relates to the offer and resale of up to an aggregate of 2,191,012 shares of common stock of Conduit Pharmaceuticals Inc. held by the selling stockholders.

8-K filing: Conduit Pharmaceuticals Inc. issued 1,853,933 shares of common stock to Sarborg Limited for $1.65 million in prepaid monthly invoices, and 410,113 shares of common stock to unrelated third parties for consulting and advisory services. As of March 31, 2025, there are 9,549,800 shares of common stock outstanding. ($1.65M proceeds)

10-K filing | 6.7M shares outstanding

S-3 filing: This prospectus relates to the offer and resale of up to an aggregate of 5,898,705 shares of common stock of Conduit Pharmaceuticals Inc. held by the selling stockholders listed in this prospectus or its permitted transferees.

8-K filing: Stock split 1-for-100 | Outstanding: 102,847,973 → 1,028,479

8-K filing: Conduit Pharmaceuticals Inc. issued 2,272,727 shares of common stock to SARBORG Limited as part of a Services Agreement. ($0.2M proceeds)

S-3 filing: This prospectus relates to the offer and resale of up to an aggregate of 75,000,000 shares of common stock of Conduit Pharmaceuticals Inc., held by the selling stockholder listed in this prospectus or its permitted transferees, which may be issued upon the conversion of the August 2024 Senior Secured Promissory Note.

10-Q filing | 102.8M shares outstanding

8-K filing: Conduit Pharmaceuticals Inc. entered into a Bridge Loan Agreement with A.G.P./Alliance Global Partners for an advance not to exceed $600,000, issuing warrants to purchase up to 2,862,596 shares of common stock at an exercise price of $0.1048 per share, and issued a promissory note to Nirland Limited for $600,000; furthermore, the company amended the existing debt agreements with Nirland, allowing conversion of the existing note into shares of common stock at Nirland's discretion.

S-3 filing: The company is filing an S-3 to offer and sell up to $100,000,000 in the aggregate of common stock and preferred stock from time to time in one or more offerings.

S-1/A filing: The company consummated the private placement of 754,000 units to the Sponsor at a price of $10.00 per unit, generating gross proceeds of approximately $7.54 million.

S-1 filing: This S-1 filing registers for resale an aggregate of up to 22,004,465 shares of common stock issued to AstraZeneca AB and Nirland Limited, with the selling securityholders potentially offering these shares publicly or through private transactions.

10-Q filing | 96.0M shares outstanding

8-K filing: Conduit Pharmaceuticals Inc. issued 9,504,465 shares of its common stock to AstraZeneca AB pursuant to a Stock Issuance Agreement as consideration for a license agreement.

8-K filing: Conduit Pharmaceuticals Inc. entered into a Senior Secured Promissory Note with Nirland Limited, issuing a note for $2,650,000 and agreeing to issue 12,500,000 shares of the Company's common stock to the Purchaser.

10-Q filing | 73.8M shares outstanding

POS AM filing: This prospectus relates to the offer and sale from time to time by the selling securityholders named in this prospectus of an aggregate of: (a) up to 8,771,470 shares of our common stock and (b) up to 16,033,000 shares of Common Stock issuable upon exercise of certain warrants.

10-K filing | 67.9M shares outstanding

S-1/A filing: This S-1/A filing from Conduit Pharmaceuticals Inc. relates to the offer and sale of 8,771,470 shares of common stock and 16,033,000 shares of common stock underlying warrants by selling securityholders.

10-Q filing | 66.1M shares outstanding

S-1 filing: This is an S-1 filing for the offer and sale from time to time by the selling securityholders of common stock, shares of common stock underlying warrants, and shares of common stock underlying an option.

8-K filing: On September 20, 2023, 2,129,662 shares of Class A common stock were redeemed in connection with the Business Combination.

8-K filing: Murphy Canyon Acquisition Corp. entered into a Subscription Agreement with Nirland Limited, where Nirland Limited will purchase $20 million in units, each consisting of one share of common stock and one warrant, at $10.00 per unit, contingent upon the closing of a Business Combination. ($20.0M proceeds)

10-Q filing | 2.9M shares outstanding

10-Q filing | 2.9M shares outstanding

10-K filing | 2.9M shares outstanding

8-K filing: Murphy Canyon Acquisition Corp. entered into a merger agreement with Conduit Pharmaceuticals Limited, where MURF will acquire Conduit for $650,000,000 payable in 65,000,000 shares of MURF Common Stock at $10.00 per share, and MURF also entered into a Subscription Agreement with an investor for $27 million units of MURF at $10.00 per unit. ($677.0M proceeds)

10-Q filing | 14.0M shares outstanding

10-Q filing | 14.0M shares outstanding

10-Q filing | 14.0M shares outstanding

10-K filing | 14.0M shares outstanding

8-K filing: Murphy Canyon Acquisition Corp. consummated its initial public offering of 11,500,000 units at $10.00 per Unit, generating gross proceeds of $115,000,000, and the underwriters exercised their option in full, resulting in the sale of 13,225,000 units in total and total gross proceeds of $132.25 million. Simultaneously with the offering, the company consummated the private placement of 754,000 units to the sponsor at a price of $10.00 per private placement unit, generating gross proceeds of approximately $7.54 million. ($139.79M proceeds)

8-K filing: Murphy Canyon Acquisition Corp. completed an initial public offering of 13,225,000 units at $10.00 per unit, generating gross proceeds of $132.25 million, and a private placement of 754,000 units to the Sponsor at $10.00 per unit, generating gross proceeds of approximately $7.54 million. ($139.79M proceeds)

S-1/A filing: This S-1/A filing is for an initial public offering of units of Murphy Canyon Acquisition Corp, where each unit consists of one share of Class A common stock and one redeemable warrant, and a concurrent private placement of units to the sponsor.

RW filing: The company requests the withdrawal of its registration statement and confirms that no securities were sold in connection with the offering.

S-1 filing: This S-1 filing is for an initial public offering of units, each consisting of one share of Class A common stock and three-quarters of one redeemable warrant, with a proposed offering amount of $150,000,000 by Murphy Canyon Acquisition Corp, a blank check company.